Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
WALTHAM, Mass., Feb. 27, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming investor conferences. The details for the three conferences are:
- The Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place on March 6, 2017. Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 3:20 pm ET.
- The 29th Annual ROTH Conference at the Ritz Carlton Hotel in Orange County, California on March 13, 2017. Michael A. Metzger, President and Chief Operating Officer of Syndax, will make a presentation at 4:30 pm PT.
- The Oppenheimer 27th Annual Healthcare Conference at the Westin New York Grand Central on March 22, 2017. Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 10:20 am ET.
A live webcast of these presentations can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers. For more information on Syndax, please visit www.syndax.com.
Investor Contacts Heather Savelle Argot Partners [email protected] Tel 646.395.3734 Media Contact Eliza Schleifstein Argot Partners [email protected] Tel 973.361.1546
